MISSISSAUGA, ON, May 19, 2022
/CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon")
(TSXV: COV) (OTCQX: CVALF), an advanced medical technologies
company, today announced that Mark
Doolittle has joined the Company as Senior Vice President,
Commercial Sales.
"I am delighted to welcome Mark to Covalon," said Brian Pedlar, Chief Executive Officer of
Covalon. "We are continuing to build a transformative leadership
team and his years of experience in commercial leadership will help
our Company as we grow our US and international business. Mark's
creativity, passion, and expertise will be an asset to us as we
expand the adoption of our infection prevention and biological
collagen solutions."
Mr. Doolittle brings over 20 years of medical and B2B sales and
marketing experience to Covalon. He has substantial leadership
experience managing high-performing teams and managing partnerships
both domestically and internationally. Prior to joining
Covalon, Mr. Doolittle spent the last 12 years at US-based Cantel
Medical, the global leader in infection prevention in GI Endoscopy.
In his most recent role, he served as the Vice President of US
Commercial. During his tenure, Cantel recorded record profits,
becoming a $1B organization,
including the medical division growing from $30M to $350M. In
2021, Cantel was acquired for $3.6B.
Throughout his career, Mr. Doolittle has held multiple
progressive roles including Vice President of Corporate Accounts,
where he gained extensive knowledge of US healthcare Group
Purchasing Organizations ("GPOs") and Integrated Delivery Networks
("IDNs"), and Vice President of Innovative Solutions, where he
focused on technology innovations in healthcare. Mr. Doolittle
holds a Bachelor's Degree from Gonzaga University.
About Covalon
Covalon Technologies Ltd. is a researcher, developer,
manufacturer, and marketer of patent-protected medical products
that improve patient outcomes and save lives in the areas of
advanced wound care, infection management and surgical procedures.
Covalon leverages its patented medical technology platforms and
expertise in two ways: (i) by developing products that are sold
under Covalon's name; and (ii) by developing and commercializing
medical products for other medical companies under development and
license contracts. The Company is listed on the TSX Venture
Exchange, having the symbol COV and trades on the OTQX Market under
the symbol CVALF. To learn more about Covalon, visit our website at
www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results, the
impact and timing of COVID-19 on operating activities and market
conditions, and other risks, any of which could cause
results, performance, or achievements to differ materially from the
results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific
to the Company. Investors should consult the Company's ongoing
quarterly filings for additional information on risks and
uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter
any forward-looking statements whether as a result of new
information, further events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-attracts-well-known-medical-industry-sales-executive-301551391.html
SOURCE Covalon Technologies Ltd.